ClinicalTrials.gg
Not yet recruitingNCT07854990CKM-T2DUpdated Oct 2, 2026

Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes

An observational study in Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome and Diabetic Kidney Disease, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Assiut University · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
231
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetes Mellitus, Type 2 by Assiut University — 15 open to participants now, 15 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Assiut University.

Planned enrollment
4th of 23
231 · median 100
Started
2026
with 9 others
Observational
23 of 25
14 open now
Primary completion
2028-03
later than 13 of 14 live
Registered
23rd of 25
by date

Among the 25 studies in Diabetes Mellitus, Type 2 by Assiut University, this one is the 4th largest by planned enrollment of the 23 observational ones that give a count, is one of 10 that started in 2026, is one of 23 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 25 studies in Diabetes Mellitus, Type 2 by Assiut University are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes Mellitus, Type 2 by Assiut University, or all of them as a file.
02

Study summary

Type 2 diabetes (T2D) is a principal driver of cardiovascular-renal-metabolic (CKM) syndrome, where metabolic, renal, and cardiac dysfunction accelerate disease progression. This cross-sectional study aims to classify adult patients with T2D attending outpatient clinics at Assiut University Hospitals across CKM stages (0-4) according to the 2023 American Heart Association (AHA) staging system. Additionally, the study identifies independent clinical and laboratory predictors of advanced CKM stages (Stages 3-4) and quantifies the therapeutic gap regarding guideline-indicated organ-protective medications (SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, statins, and MRAs).

Read the detailed description

Type 2 diabetes (T2D) affects a rapidly growing proportion of the global population, ranking alongside cardiovascular and chronic kidney disease as leading causes of death worldwide. T2D accelerates cardiovascular-renal-metabolic (CVRM) dysfunction through chronic inflammation, neurohormonal activation, and endothelial injury. The AHA 2023 staging framework categorizes CKM into Stage 0 (no risk), Stage 1 (excess adiposity), Stage 2 (metabolic risk factors including T2D, hypertension, early CKD), Stage 3 (subclinical CVD/CKD), and Stage 4 (clinical CVD or advanced CKD).

  • Despite strong clinical trial evidence, a persistent therapeutic gap remains, with fewer than half of eligible T2D patients receiving guideline-indicated organ-protective therapies.
  • In this single-visit observational study conducted at Assiut University Hospitals, eligible adult T2D patients will undergo structured clinical examination, standard laboratory evaluations (fasting blood glucose, HbA1c, lipid profile, serum creatinine/eGFR, spot urine albumin-to-creatinine ratio, serum potassium), 12-lead ECG, abdominal ultrasound, and echocardiography. Participants will be staged according to CKM criteria. Logistic regression models will determine independent predictors of advanced CKM disease, and prescribed regimens will be audited against guidelines to calculate drug class-specific therapeutic gaps.
03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Cardiovascular-Kidney-Metabolic Syndrome
  • Diabetic Kidney Disease

Keywords

  • CKM syndrome, SGLT2 inhibitors, RAAS inhibitors, Therapeutic gap, Diabetic nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (aged ≥18 years) with an established diagnosis of type 2 diabetes mellitus (ADA criteria) for at least 6 months, accompanied by diabetic kidney disease (DKD), obesity, or cardiac involvement, attending routine follow-up at the outpatient diabetes and internal medicine clinics of Assiut University Hospitals, Assiut, Egypt

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Established diagnosis of type 2 diabetes mellitus (ADA criteria) for at least 6 months with diabetic kidney disease (DKD), obesity, or cardiac affection.
  • Willing and able to give written .

Exclusion criteria

Exclusion Criteria:

  • Type 1 or secondary diabetes.
  • Already on chronic dialysis or with a functioning kidney transplant.
  • Pregnancy.
  • Active or terminal illness with \<6 months.
  • Incomplete essential clinical or laboratory data that cannot be obtained at the visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
231 participants (estimated)
Patient registry
No

Groups and cohorts

  • adult wiith type 2 diabetes

    Adult patients aged 18 years and older with established type 2 diabetes mellitus (duration ≥6 months) and diabetic kidney disease, obesity, or cardiac affection attending outpatient clinics at Assiut University Hospitals.

    Diagnostic Test: clinical and laboratory CKM staging evaluation

Interventions

  • Diagnostic testclinical and laboratory CKM staging evaluation

    Comprehensive single-visit assessment including clinical examination (BP, BMI, waist circumference, 12-lead ECG), routine laboratory testing (fasting blood glucose, HbA1c, lipid profile, serum creatinine/eGFR, spot urine albumin-to-creatinine ratio, serum potassium), abdominal ultrasound, and echocardiography to classify CKM syndrome stage (0-4) per AHA 2023 criteria and evaluate current prescribing patterns of organ-protective therapies\[span\_1\](start\_span)\[span\_1\](end\_span).

06

What researchers measure

Primary outcomes

  1. CKM Syndrome Stage Distribution and Clinical Predictors

    Classification of participants into CKM stages (0-4) per 2023 AHA criteria, and determination of independent clinical and laboratory predictors (e.g., age, BMI, eGFR, UACR, comorbidities) associated with advanced CKM stages (Stages 3-4) using multivariate logistic regression.

    Time frame: Single outpatient visit

Secondary outcomes

  1. Therapeutic Gap for Organ-Protective Therapies

    Percentage of eligible patients not prescribed guideline-indicated organ-protective therapies (SGLT2 inhibitors, GLP-1 receptor agonists, ACEi/ARB, statins, and mineralocorticoid receptor antagonists), calculated per drug class and across CKM stages.

    Time frame: Single outpatient visit

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Mar 20, 2028
CompletionEst.
Jul 10, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854990
Lead sponsor
Assiut University
Responsible party
Omima Darwish Ahmed (resident doctor of internal medicine, Assiut University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Mar 20, 2028 (estimated)
Completion
Jul 10, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

omima darwish hamam, resident doctor
Contact
omima.18313215@med.aun.edu.eg
+201144062818

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion